Navigation Links
S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders
Date:12/2/2009

of pharmacodynamic (PD) biomarker assays for SB1518 will be presented in a poster, demonstrating PD target efficacy of SB1518 in animal tumor models, as well as, in patients in ongoing Phase 1 clinical studies for advanced leukemias, myeloproliferative diseases and lymphoma. The fourth poster will highlight the effects of SB1518 on ex vivo expanded polycythemia vera (PV) erythroid progenitors which correlate with clinical observations.

Poster No.: 3905, Time: 6-8 p.m. CST, Monday, Dec. 7, 2009, Location: Hall E (Ernest N. Morial Convention Center)

Phase I Dose-Escalation Trial of SB1518, a Novel JAK2/FLT3 Inhibitor, in Acute and Chronic Myeloid Diseases, Including Primary or Post-Essential Thrombocythemia/ Polycythemia Vera Myelofibrosis

SB1518, which is a potent ATP-competitive inhibitor of JAK2 (IC50=22nM), JAK2V617F mutant (IC50=19nM), FLT3 (IC50=22nM) and its mutant D835Y (IC50=6nM), is being tested to determine its safety, tolerability and PK/PD profile when administered orally once daily continuously in 28-day cycles. SB1518 was well tolerated at doses up to 500 mg daily in patients with advanced myelofibrosis (MF) and acute myelogenous leukemias (AML), and shows clinical activity in MF patients with splenomegaly.

Oral Presentation Abstract No.: 588, Time: 4 p.m. CST, Monday, Dec. 7, 2009, Location: Room R02-R05

Phase 1 Study of the Novel Oral JAK2 Inhibitor SB1518 in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity

A Phase 1 dose escalating study of the novel JAK2 small molecule inhibitor SB1518 is being conducted in patients with relapsed Hodgkin (HL) and non-Hodgkin lymphomas (NHL). The primary objectives are to examine the safety and efficacy of SB1518 in this patient population. Patients are treated at four dose levels (100 mg, 200 mg, 300 mg, and 400 mg) orally daily without interruption.
'/>"/>

SOURCE S*BIO Pte Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. S*BIO Receives Orphan Drug Designation for JAK2 Inhibitor SB1518 for the Treatment of Myeloproliferative Disorders
2. S*BIO Completes US$26 Million Equity Financing
3. S*BIO and Tragara Announce an Exclusive Worldwide License Agreement for Novel Multi-kinase Inhibitor SB1317
4. S*BIO Receives BioSpectrum Editors Choice, Emerging BioScience Company of Singapore Award
5. Novel Technology Breaks Through Cancer Pain
6. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
7. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
8. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
9. New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
10. NIST team develops novel method for nanostructured polymer thin films
11. GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... , May 5, 2015 Roka Bioscience, Inc. ... providing advanced testing solutions for the detection of foodborne pathogens, ... at the Bank of America Merrill Lynch 2015 Health Care ... be held at Encore at the Wynn, Las ... of the presentation will be available through the investor relations ...
(Date:5/5/2015)... , May 5, 2015 Psyche Systems Corporation ... which offers a first-of-its-kind platform that helps labs comply ... lab results, transforms the way patients engage with these ... Luminate Health provides a HIPAA-compliant digital platform that ... manage, and understand their lab results, and uniquely connects ...
(Date:5/5/2015)... 5, 2015 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") ... , President and Chief Executive Officer, will present ... DATE:  Thursday, May 7, 2015     TIME:  11:30 am ... > click the red "register/ watch presentations" button ... online event where investors are invited to ask ...
(Date:5/5/2015)... , May 05, 2015 Research and ... the addition of the "Clinical Laboratory, Molecular ... Forecasts 2015 to 2019 - Europe Version" ... developments especially in the area of molecular diagnostics ... growing and evolving world market that is moving ...
Breaking Biology Technology:Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 2Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 3ImmunoCellular Therapeutics to Webcast Live at VirtualInvestorConferences.com on May 7 2European Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market 2015-2019 2
... at the Midwest Venture Summit on May 20 in Chicago. ... selecting only a handful of presenters out of the applicants ... be reviewed by a panel of investors that has been ... that each company is producing and developing, as well as ...
... company moving to Madison from Chicago is being welcomed ... , ,Governor Jim Doyle announced earlier this week that ... the Department of Commerce Technology Venture Fund ... to help the company purchase new equipment and hire ...
... system. Image courtesy of GE Healthcare. Wisconsin Governor ... $10 million for a grant and loan program to ... , ,"I am committed to ensuring that all Wisconsin ... I am pleased to unveil a proposal of my ...
Cached Biology Technology:Follow the money 2Follow the money 3Doyle proposes $10M to expand use of electronic medical records 2Doyle proposes $10M to expand use of electronic medical records 3
(Date:4/6/2015)... Conn. , Apr. 6, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/143028 for ... COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces a ... payments. This patent surrounds the use of miniature ...
(Date:4/2/2015)... -- At its 2015 ACMG Annual Clinical Genetics Meeting ... American College of Medical Genetics and Genomics (ACMG) announced ... Members of the ACMG Board of Directors serve as ... its policies and programs. ACMG is the national organization ... eventful time in medical genetics and genomics.  We are ...
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... for its touch fingerprint sensor FPC1025 from the distributor ... Deliveries will commence during Q2 2015 although the major ... 2015. The sensors will be used by smartphone manufacturers ... of 110 MSEK is included in the communicated revenue ...
Breaking Biology News(10 mins):NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2
... Institutes of Health Director Francis S. Collins, M.D., Ph.D., today ... new director of the National Institute of General Medical Sciences. ... of the Department of Biology at the Massachusetts Institute of ... spring of 2012. "Dr. Kaiser has tremendous energy and ...
... A new study has shown that racehorses are extremely ... can adapt very quickly to sudden shifts in the 24-hour ... with unexpected benefits on their physical performance. The ... of Medical and Veterinary Sciences is published in the ...
... On the heels of a summit on managing extreme events ... National Academy of Sciences and the Willis Research Network, part ... headquartered in the U.K., pledged to continue exploring activities aimed ... extreme events. Although 2011 has been a notable year ...
Cached Biology News:Cell biologist Chris A. Kaiser to lead NIH's National Institute of General Medical Sciences 2Cell biologist Chris A. Kaiser to lead NIH's National Institute of General Medical Sciences 3Light dependency underlies beneficial jetlag in racehorses 2Light dependency underlies beneficial jetlag in racehorses 3US science academy and global reinsurance broker spark 2US science academy and global reinsurance broker spark 3US science academy and global reinsurance broker spark 4
...
... Kit contains reagents required to perform a ... the bisulfite reaction, all unmethylated cytosines are ... while 5-methylcytosines remain unaltered. Thus, the sequence ... on whether the DNA is originally methylated ...
... contains a unique β-agarose digesting enzyme developed ... intact DNA and RNA from low melting ... TAE, TBE, MOPS, or phosphate buffers. The ... TAE, TBE, MOPS, and phosphate electrophoresis buffers ...
...
Biology Products: